|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
InScape® ER/PR/HER-2 Quantitative IHC with Interpretation [16706X]
Test Code16706
CPT Codes
88361 (x3)
Preferred Specimen
Formalin-fixed, paraffin-embedded tissue block
Other Acceptable Specimens
Minimum: 9 unstained, positively charged slides
Instructions
Invasive primary or metastatic breast or gastric cancer formalin-fixed, paraffin-embedded tissue or charged/+slides from formalin-fixed, paraffin-embedded tissue. Specimen must be fixed in 10% neutral buffered formalin. Cold ischemic time of less than 1 hour and fixation between 6 and 72 hours is recommended.
Pathology report must accompany paraffin block or slides. Information required in this report includes: Physician identification, specimen identifiers (case and block number), specimen site and type, collection date, collection time, tissue processing used (routine or microwave), cold ischemic time, type of fixative, duration of fixation, pathologic diagnosis, and IHC score, if performed elsewhere. Ship at room temperature. Do not freeze.
Pathology report must accompany paraffin block or slides. Information required in this report includes: Physician identification, specimen identifiers (case and block number), specimen site and type, collection date, collection time, tissue processing used (routine or microwave), cold ischemic time, type of fixative, duration of fixation, pathologic diagnosis, and IHC score, if performed elsewhere. Ship at room temperature. Do not freeze.
Transport Container
IHC Specimen Transport Kit
Transport Temperature
Room temperature
Specimen Stability
Room temperature: Indefinitely
Refrigerated: Indefinitely
Frozen: Unacceptable
Refrigerated: Indefinitely
Frozen: Unacceptable
Methodology
Immunohistochemistry (IHC)
Setup Schedule
Set up: Mon-Fri; Report available: Next day
Reference Range
See Medical Report
Clinical Significance
Breast cancer is a heterogeneous disease and there is a continual drive to identify markers that will aid in predicting prognosis and response to therapy. Estrogen receptor (ER) is probably the most powerful predictive marker in breast cancer management, both in determining prognosis and in predicting response to hormone therapies. Progesterone receptor (PR) is an estrogen-regulated gene and its expression is therefore thought to indicate a functioning ER pathway, although its value is less well established. HER-2 status, either by Immunohistochemistry or FISH, has also become a routine prognostic and predictive factor in breast cancer.
